Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506)

被引:2
|
作者
Chen, YW [1 ]
Smith, ML [1 ]
Sheets, MP [1 ]
Ballaron, SJ [1 ]
Trevillyan, JM [1 ]
Fey, TA [1 ]
Gauvin, DM [1 ]
Kolano, R [1 ]
Pong, MS [1 ]
Hsieh, GC [1 ]
Bauch, J [1 ]
Marsh, K [1 ]
Carter, G [1 ]
Luly, J [1 ]
Djuric, S [1 ]
Mollison, KW [1 ]
机构
[1] Abbott Labs, Immunol Dis Res, Abbott Pk, IL 60064 USA
关键词
ex vivo; immunosuppression; FK506; pigs; IL-2;
D O I
10.1006/clim.1998.4625
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To assess the duration of immunosuppression in FK506-dosed pigs, an undiluted whole blood assay was established to measure reactivities of T cells in their physiological milieu. PMA and ionomycin were shown to induce IL-2 production in swine blood. The IC50 of FK506 in inhibiting IL-2 production in whole blood and isolated PBMC stimulated with PMA and ionomycin measured 1.2 and 0.04 nM, respectively. These data underscore the influence of red blood cells and plasma proteins on drug potency. IL-2 levels were determined in blood drawn immediately before and 1, 24, 48, and 72 h after iv dosing. For pigs dosed with 0.05 mg/kg, 50% recovery of IL-2 production was observed at 16 h and 100% at 35 h after dosing. For pigs dosed with 0.15 mg/kg; 50% recovery was observed at 38 h and 100% at 72 h. Blood concentrations of FK506 at 50 and 100% recovery of IL-2 production measured 10.8 and 2.2 nM for pigs dosed with 0.05 mg/kg and 6.1 and 1.1 nM:for pigs dosed with 0.15 mg/kg, respectively. These concentrations are severalfold higher than predicted from the IC,, of FK506 for inhibiting IL-2 production in the whole blood assay. These data suggest that the true potency of FK506 in blood after dosing is influenced by additional factors, which could include plasma protein binding, the presence of active or interfering metabolites, serum interfering factors, and sequestration of drug in blood cells. Our results demonstrate the utility of an undiluted whole blood assay for assessing the duration of immunosuppression in drug-dosed animals and emphasize the importance of assessing drug potency in the whole blood environment ex vivo. (C) 1999 Academic Press.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 22 条
  • [1] Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay
    Alak, AM
    Lizak, PP
    THERAPEUTIC DRUG MONITORING, 1996, 18 (03) : 267 - 272
  • [2] Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation
    Dmitrewski, J
    Krentz, AJ
    Mayer, AD
    Buckels, JAC
    Barnes, AD
    Smith, J
    Nattrass, M
    DIABETES OBESITY & METABOLISM, 2001, 3 (04) : 287 - 292
  • [3] In Vitro and In Vivo Release Characteristics of Tacrolimus (FK506) from an Episcleral Drug-Delivery Implant
    Mai, Shuyi
    Lin, Leilei
    Yang, Wei
    Deng, Xuejiao
    Xie, Zhiyong
    Zong, Yao
    Li, Yujie
    Gao, Qianying
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 30 (08) : 670 - 680
  • [4] FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction
    Tokunaga, Y
    Alak, AM
    PHARMACEUTICAL RESEARCH, 1996, 13 (01) : 137 - 140
  • [5] In vitro-in vivo extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure
    Oda, Kazuo
    Yamano, Katsuhiro
    Otsuka, Yukio
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2015, 36 (05) : 265 - 274
  • [6] Cyclosporin A and tacrolimus (FK506) differentially alter T-cell receptor expression in vivo
    Miller, Jamie Leigh
    Ericson, Solveig Gronning
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2007, 29 (01) : 105 - 118
  • [7] A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents
    MacFarlane, G
    Scheller, D
    Ersfeld, D
    Jensen, T
    Jevans, A
    Wong, PY
    Kobayashi, M
    THERAPEUTIC DRUG MONITORING, 1996, 18 (06) : 698 - 705
  • [8] VALIDATION AND QUALITY ASSURANCE PROGRAM FOR MONITORING TACROLIMUS (FK-506) CONCENTRATIONS IN PLASMA AND WHOLE-BLOOD
    DAMBROSIO, R
    GIRZAITIS, N
    JUSKO, WJ
    THERAPEUTIC DRUG MONITORING, 1993, 15 (05) : 414 - 426
  • [9] Isolating the whole complex of target proteins of FK506 using affinity resins from novel solid phases
    Teruki Takahashi
    Takaaki Shiyama
    Tomoko Mori
    Ken Hosoya
    Akito Tanaka
    Analytical and Bioanalytical Chemistry, 2006, 385 : 122 - 127
  • [10] Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression
    N. Singh
    T. Gayowski
    M. M. Wagener
    I. R. Marino
    European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16 : 821 - 826